As a dual board–certified hematologist and palliative care physician, I am convinced that numerous patients with advanced hematologic malignant neoplasms would benefit from early palliative care intervention, given that many of them will not be cured, and suffer from several distressing symptoms. However, for this patient population, early palliative care access is still uncommon, and far less common than for patients with solid tumors. Many patients with advanced hematologic malignant neoplasms receive aggressive treatments or chemotherapy while nearing the end of life and often die in the intensive care unit, even though it is not consistent with their expressed wishes.¹

作为一名获得双重委员会认证的血液学家和姑息治疗医师，我深信，许多晚期血液系统恶性肿瘤患者将从早期姑息治疗干预中受益，因为他们中的许多人无法治愈，并且会出现一些令人痛苦的症状。但是，对于这种患者群体，早期姑息治疗的使用仍然不常见，并且远不如实体瘤患者常见。许多晚期血液系统恶性肿瘤患者在生命快要结束时会接受积极的治疗或化学疗法，并且即使在重症监护室中表达的意愿与他们的意愿不一致，也往往会在重症监护病房死亡。^1个